PT3452053T - Método de tratamento do cancro urotelial do trato inferior - Google Patents
Método de tratamento do cancro urotelial do trato inferiorInfo
- Publication number
- PT3452053T PT3452053T PT177935236T PT17793523T PT3452053T PT 3452053 T PT3452053 T PT 3452053T PT 177935236 T PT177935236 T PT 177935236T PT 17793523 T PT17793523 T PT 17793523T PT 3452053 T PT3452053 T PT 3452053T
- Authority
- PT
- Portugal
- Prior art keywords
- urothelial cancer
- treating lower
- lower tract
- tract urothelial
- treating
- Prior art date
Links
- 206010044412 transitional cell carcinoma Diseases 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M31/00—Devices for introducing or retaining media, e.g. remedies, in cavities of the body
- A61M31/002—Devices for releasing a drug at a continuous and controlled rate for a prolonged period of time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/02—General characteristics of the apparatus characterised by a particular materials
- A61M2205/0216—Materials providing elastic properties, e.g. for facilitating deformation and avoid breaking
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Epoxy Compounds (AREA)
- Saccharide Compounds (AREA)
- Materials For Medical Uses (AREA)
- Media Introduction/Drainage Providing Device (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662333151P | 2016-05-06 | 2016-05-06 | |
| US201762443614P | 2017-01-06 | 2017-01-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT3452053T true PT3452053T (pt) | 2023-03-03 |
Family
ID=60203435
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT177935236T PT3452053T (pt) | 2016-05-06 | 2017-05-05 | Método de tratamento do cancro urotelial do trato inferior |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20190388338A1 (enExample) |
| EP (2) | EP3452053B1 (enExample) |
| JP (3) | JP7712055B2 (enExample) |
| KR (2) | KR20220123317A (enExample) |
| CN (2) | CN109475571A (enExample) |
| AU (1) | AU2017261371B2 (enExample) |
| CA (1) | CA3023274A1 (enExample) |
| ES (1) | ES2940227T3 (enExample) |
| FI (1) | FI3452053T3 (enExample) |
| HR (1) | HRP20221544T1 (enExample) |
| HU (1) | HUE060965T2 (enExample) |
| IL (2) | IL295592A (enExample) |
| LT (1) | LT3452053T (enExample) |
| MX (2) | MX389296B (enExample) |
| NZ (3) | NZ787786A (enExample) |
| PL (1) | PL3452053T3 (enExample) |
| PT (1) | PT3452053T (enExample) |
| RS (1) | RS64032B1 (enExample) |
| RU (2) | RU2022100624A (enExample) |
| SG (2) | SG10201913416PA (enExample) |
| SI (1) | SI3452053T1 (enExample) |
| SM (1) | SMT202300047T1 (enExample) |
| WO (1) | WO2017193098A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI3370768T1 (sl) | 2015-11-03 | 2022-04-29 | Janssen Biotech, Inc. | Protitelesa, ki se specifično vežejo na PD-1, in njihove uporabe |
| CA3037380A1 (en) | 2016-10-11 | 2018-04-19 | Agenus Inc. | Anti-lag-3 antibodies and methods of use thereof |
| WO2019023388A1 (en) * | 2017-07-25 | 2019-01-31 | Taris Biomedical Llc | METHODS OF TREATING TUMOR METASTASIS |
| PE20210041A1 (es) * | 2017-11-08 | 2021-01-08 | Taris Biomedical Llc | Metodos de tratamiento y terapia de mantenimiento para el cancer de vejiga con gemcitabina |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY30915A1 (es) * | 2007-02-16 | 2008-09-02 | Smithkline Beecham Corp | Método de tratamiento de canceres |
| US8343516B2 (en) | 2009-06-26 | 2013-01-01 | Taris Biomedical, Inc. | Solid drug tablets for implantable drug delivery devices |
| US8679094B2 (en) | 2009-12-17 | 2014-03-25 | Taris Biomedical, Inc. | Implantable device with intravesical tolerability and methods of treatment |
| WO2011153009A1 (en) * | 2010-06-02 | 2011-12-08 | Abraxis Bioscience, Llc | Methods of treating bladder cancer |
| PT2600800T (pt) | 2010-08-05 | 2020-11-05 | Taris Biomedical Llc | Dispositivo de administração de drogas por stent ureteral, kit e método |
| WO2012106714A1 (en) | 2011-02-04 | 2012-08-09 | Taris Biomedical, Inc. | Implantable device for controlled release of low solubility drug |
| US20150216937A1 (en) * | 2012-03-29 | 2015-08-06 | Altor Bioscience Corporation | Methods for treating neoplasia |
| KR102383496B1 (ko) | 2012-08-31 | 2022-04-08 | 타리스 바이오메디컬 엘엘씨 | 젬시타빈을 포함하는 전립선 질환의 치료를 위한 약물 전달 시스템과 방법 |
| RU2657591C2 (ru) * | 2012-08-31 | 2018-06-14 | ТАРИС Биомедикал ЛЛК | Способ лечения рака мочевого пузыря оксалиплатином, соответствующее устройство его доставки, способ и устройство его введения |
| JP2016508842A (ja) | 2013-03-05 | 2016-03-24 | タリス バイオメディカル エルエルシー | 装置の開口部を通じて制御された薬物放出のための薬物送達装置及び方法 |
| EP2968120A1 (en) | 2013-03-15 | 2016-01-20 | TARIS Biomedical LLC | Drug delivery devices and methods for drug delivery |
| SG11201507294WA (en) | 2013-03-15 | 2015-10-29 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
| WO2015026813A1 (en) | 2013-08-19 | 2015-02-26 | Taris Biomedical Llc | Multi-unit drug delivery devices and methods |
| HRP20251264T1 (hr) * | 2014-03-06 | 2025-12-05 | Taris Biomedical Llc | Sustavi za primjenu lijeka i metode za liječenje karcinoma mokraćnog mjehura gemcitabinom |
| KR102391761B1 (ko) | 2014-06-26 | 2022-04-27 | 타리스 바이오메디컬 엘엘씨 | 탄성 폴리머-약물 매트릭스 시스템을 포함하는 방광내 약물 전달 장치 및 방법 |
| WO2016172704A1 (en) | 2015-04-23 | 2016-10-27 | Taris Biomedical Llc | Drug delivery devices with drug-permeable component and methods |
-
2017
- 2017-05-05 ES ES17793523T patent/ES2940227T3/es active Active
- 2017-05-05 SG SG10201913416PA patent/SG10201913416PA/en unknown
- 2017-05-05 IL IL295592A patent/IL295592A/en unknown
- 2017-05-05 RU RU2022100624A patent/RU2022100624A/ru unknown
- 2017-05-05 KR KR1020227028547A patent/KR20220123317A/ko not_active Ceased
- 2017-05-05 WO PCT/US2017/031445 patent/WO2017193098A1/en not_active Ceased
- 2017-05-05 SI SI201731301T patent/SI3452053T1/sl unknown
- 2017-05-05 US US16/099,179 patent/US20190388338A1/en active Pending
- 2017-05-05 AU AU2017261371A patent/AU2017261371B2/en active Active
- 2017-05-05 MX MX2018013432A patent/MX389296B/es unknown
- 2017-05-05 SM SM20230047T patent/SMT202300047T1/it unknown
- 2017-05-05 CN CN201780040391.1A patent/CN109475571A/zh active Pending
- 2017-05-05 NZ NZ787786A patent/NZ787786A/en unknown
- 2017-05-05 HU HUE17793523A patent/HUE060965T2/hu unknown
- 2017-05-05 PL PL17793523.6T patent/PL3452053T3/pl unknown
- 2017-05-05 NZ NZ748252A patent/NZ748252A/en unknown
- 2017-05-05 SG SG11201809838VA patent/SG11201809838VA/en unknown
- 2017-05-05 CA CA3023274A patent/CA3023274A1/en active Pending
- 2017-05-05 LT LTEPPCT/US2017/031445T patent/LT3452053T/lt unknown
- 2017-05-05 CN CN202410626384.1A patent/CN118453872A/zh active Pending
- 2017-05-05 RS RS20230163A patent/RS64032B1/sr unknown
- 2017-05-05 HR HRP20221544TT patent/HRP20221544T1/hr unknown
- 2017-05-05 KR KR1020187035297A patent/KR102435709B1/ko active Active
- 2017-05-05 FI FIEP17793523.6T patent/FI3452053T3/fi active
- 2017-05-05 RU RU2018142908A patent/RU2764747C2/ru active
- 2017-05-05 EP EP17793523.6A patent/EP3452053B1/en active Active
- 2017-05-05 PT PT177935236T patent/PT3452053T/pt unknown
- 2017-05-05 NZ NZ787824A patent/NZ787824A/en unknown
- 2017-05-05 IL IL262746A patent/IL262746B/en unknown
- 2017-05-05 JP JP2018558199A patent/JP7712055B2/ja active Active
- 2017-05-05 EP EP22212024.8A patent/EP4209221A1/en active Pending
-
2018
- 2018-11-01 MX MX2021013461A patent/MX2021013461A/es unknown
-
2021
- 2021-10-21 JP JP2021172052A patent/JP2022009327A/ja not_active Withdrawn
-
2023
- 2023-12-07 JP JP2023206570A patent/JP2024028881A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL275663A (en) | Cancer treatment methods | |
| IL263925A (en) | Methods of treating ovarian cancer | |
| ZA201804227B (en) | Methods of treating cancer | |
| IL255189A0 (en) | Cancer treatment methods | |
| IL255569A (en) | Methods of treating cancer using anti-ox40 antibodies | |
| HUE052106T2 (hu) | Eljárás rák kezelésére | |
| SG10201801562PA (en) | Combination method for treatment of cancer | |
| IL262342A (en) | Cancer treatment methods | |
| IL262005A (en) | Methods of treating cancer in children | |
| ZA201808258B (en) | Methods of treating pancreatic cancer | |
| ZA201802481B (en) | Novel biomarkers and methods of treating cancer | |
| IL262746A (en) | A method for treating urothelial cancer in the lower system | |
| ZA201908539B (en) | Method of treatment of cancer | |
| IL263835A (en) | Exosome-guided treatment of cancer | |
| GB201717945D0 (en) | Method for treatment of cancer | |
| SG11202005163PA (en) | Methods of treating cancer | |
| IL269123A (en) | Methods of treating cancer | |
| GB201510197D0 (en) | Method of treating ovarian cancer | |
| GB201622214D0 (en) | treatment of cancer | |
| GB201604621D0 (en) | Treatment of cancer | |
| GB201604293D0 (en) | Treatment of cancer |